This already seems to imply the four drugs have approval since the next section is a placeholder for the three are for drugs with approvals “in the coming months”!
Four specific substances classified as monoclonal antibodies– Bamlanivimab, Etesevimab, Leronlimab and REGN-COV2—have new PCS codes to track their use in treating COVID-19. Leronlimab is administered by subcutaneous injection, and the other three substances are administered via IV infusion. XW013K6 Introduction of Leronlimab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 XW043E6 Introduction of Etesevimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6 XW033E6 Introduction of Etesevimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6 XW033F6 Introduction of Bamlanivimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6 XW043F6 Introduction of Bamlanivimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6 XW033G6 Introduction of REGN-COV2 Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6 XW043G6 Introduction of REGN-COV2 Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6 Three non-specific monoclonal antibody codes were added to allow tracking of other monoclonal antibody drugs approved for treatment of COVID-19 in the coming months. XW033H6 Introduction of Other New Technology Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6 XW043H6 Introduction of Other New Technology Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6 XW013H6 Introduction of Other New Technology Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6